In the last two decades, decellularized native aortic valve (AV) has been investigated as tissue engineered heart valve (TEHV) replacements due to their potential to develop into a viable valve.[1] Decellularization removes major immunogenic cellular components. After repopulated with recipient’s cells, TEHV can be readily used because of the necessary functional design.[2] However, several problems with this approach have been identified, such as insufficient cell infiltration, mechanical deterioration, formation of fibrous sheath on implantation, and reduced orifice area after surgery.[3]

This content is only available via PDF.
You do not currently have access to this content.